Table 2.

Summary of selected clinical studies with radiofrequency ablation for the treatment of Stage I non-small cell lung cancer

Study Author, Year (ref)	No. of Patients	Pathology	Duration of Follow-up	Outcome Results
Simon et al., 2008 (23)	75	Stage I NSCLC	Median: 20.5 months*	Estimated overall survival 1, 2 and 5 years was 78%, 57% and 27% Median survival: 29 months.
Lencioni et al, 2008 (22)	13	Stage I NSCLC	Mean: 15 months*	Overall Survival at 2 year –75% (1 year not provided)
Fernando et al, 2005 (16)	18	NSCLC (Stage I, 9 patients)	Median: 14 months*	Local Progression – 38% of lesions Median PFI – 17.6 months
Ambrogi et al, 2006 (19)	54	NSCLC & Metastases	Mean: 23.7 months*	Median Local PFI – 24.1 months
Hiraki et al, 2007 (21)	20	Stage I NSCLC	Median: 21 months	Local Progression: 35% Estimated overall 1, 2 and 3 year survival: 90%, 84% and 74% respectively
Pennathur et al, 2007 (18)	19	Stage I NSCLC	Mean:29 months	Overall Survival at 1 year – 95%, 2 years: 68%; Median Survival – NR Local Progression:42% Median time to Local Progression – 27 months
Beland et al 2010 (24)	79	NSCLC (Stage I, 67 patients)	Mean: 16 months	Overall recurrence in 43% Median disease free survival 23 months
Lanuti et al 2009 (25)	31	Stage I NSCLC	Median: 17.3 Months	2 year survival: 78% median survival: 30 months Local Progression: 31.5%

PFI: Progression Free Interval

NR: Not reached

^*Follow-up not provided specifically for Stage I and includes all patients (primary and metastatic lung cancer) in this report